We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Protagonist Therapeutics has closed the worldwide license and collaboration transaction for PTG-200 with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson